Ignite Creation Date:
2024-07-17 @ 11:09 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06465264
Status:
COMPLETED
Last Update Posted:
2024-06-28
First Post:
2024-06-13
Brief Title:
To Assess Allisartan IsoproxilAmlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
Sponsor:
Shenzhen Salubris Pharmaceuticals Co Ltd
Organization:
Shenzhen Salubris Pharmaceuticals Co Ltd
Study Overview
Official Title:
Efficacy and Safety of Allisartan IsoproxilAmlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil A Phase III Multicenter Randomized Double-blind Parallel-controlled 52-week Clinical Study
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of the study will be to assess the efficacy and safety of Allisartan IsoproxilAmlodipine 240 mg5 mg in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Amlodipine besylate5 mg or Allisartan Isoproxil 240 mg
Detailed Description:
Amlodipine belongs to the calcium channel blocker CCB class of drugs which acts as an antihypertensive agent mainly via blocking calcium channels on the vascular smooth muscle cells to dilate blood vessels
Allisartan Isoproxil belongs to the ARB class of drugs which can effectively exert antihypertensive effects
The combination of dihydropyridine CCBs and ARBs exerts synergistic antihypertensive effects
Allisartan Isoproxil belongs to the ARB class of drugs which can effectively exert antihypertensive effects
The combination of dihydropyridine CCBs and ARBs exerts synergistic antihypertensive effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None